Αρχική World News FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory... World News FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma Από Ogkologos - 25 Μαρτίου, 2026 312 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MajesTEC-3 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Cómo encontrar la fuerza interior me ayudó a recuperarme del cáncer 30 Δεκεμβρίου, 2020 What Is Pancreatic Enzyme Replacement Therapy in Cancer Care? 22 Ιουνίου, 2021 UK sunburn risk: Third of adults more likely to protect their... 2 Αυγούστου, 2021 ¿Puede una biopsia hacer que mi cáncer se disemine? 9 Δεκεμβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS A Positive Trend in OS Improvement Favours Atezolizumab Compared to Best... iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with... FDA Approves Enfortumab Vedotin-ejfv with Pembrolizumab for Locally Advanced or Metastatic... Dr. Alan S. Rabson, Long-Time NCI Deputy Director and Cancer Research...